GlassScriptPhysician profile
Logan D Schneider
NPI 1689995870
$505,794.63
in general payments reported to CMS, 2019-2025
9 companies · $128K in 2025
The $128K reported for 2025 was more than what 98% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $32K · 2021: $62K · 2022: $100K · 2023: $108K · 2024: $66K · 2025: $128K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $141K · Consulting Fee: $86K · Travel and Lodging: $37K · Honoraria: $29K · Food and Beverage: $8,043 · Education: $51.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $140,655.00 |
| Consulting Fee | $86,466.35 |
| Travel and Lodging | $37,181.44 |
| Honoraria | $29,225.00 |
| Food and Beverage | $8,043.03 |
| Education | $51.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $427,316.49 | 2019-2025 | Xywav |
| Axsome Therapeutics, INC. | $27,903.70 | 2023-2025 | Sunosi |
| Eisai INC. | $18,313.66 | 2021-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $13,553.23 | 2024-2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $11,423.91 | 2025 | |
| Harmony Biosciences LLC | $4,371.44 | 2020-2025 | Wakix |
| Acadia Pharmaceuticals INC | $1,900.00 | 2020 | |
| Lundbeck LLC | $900.00 | 2024 | Rexulti |
| Ucb, INC. | $112.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.